Related Experiment Videos
Prostate cancer with small-cell morphology: an immunophenotypic subdivision
Constantina Petraki1, Michael Vaslamatzis, Kalliopi Petraki
1Department of Pathology, Evangelismos Hospital, Athens, Greece. nellitsa@vip.gr
Scandinavian Journal of Urology and Nephrology
|November 24, 2005
Summary
Undifferentiated prostatic carcinoma with small-cell morphology (U-PC-SCM) can be classified into two groups based on immunophenotype. Neuroendocrine U-PC-SCM shows a favorable response to cisplatin and etoposide chemotherapy.
Area of Science:
- Oncology
- Pathology
- Immunohistochemistry
Background:
- Prostatic carcinoma with small-cell morphology (U-PC-SCM) presents diagnostic challenges.
- Immunophenotypic analysis is crucial for differentiating subtypes of U-PC-SCM.
Purpose of the Study:
- To investigate the immunophenotypic characteristics of U-PC-SCM.
- To determine the clinical outcomes associated with different U-PC-SCM subtypes.
Main Methods:
- Immunohistochemistry was performed on 16 U-PC-SCM patient samples.
- Antibodies tested included prostate-specific antigen, neuron-specific enolase, chromogranin, and Ki-67/MIB1.
Main Results:
- Two distinct groups were identified: U-PC (Gleason score 10) and neuroendocrine small-cell carcinoma.
- Neuroendocrine U-PC-SCM showed limited response to androgen blockade but responded well to cisplatin + etoposide chemotherapy, with complete responses exceeding 14 and 22 months.
Conclusions:
- U-PC-SCM with a neuroendocrine immunophenotype is a distinct entity.
- Cisplatin plus etoposide chemotherapy is an effective treatment for neuroendocrine U-PC-SCM.